Walleye Trading’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23M | Buy |
51,400
+20,300
| +65% | +$9.47M | 0.04% | 460 |
|
|
2025
Q4 | $14.1M | Sell |
31,100
-14,500
| -32% | -$6.25M | 0.02% | 764 |
|
|
2025
Q3 | $17.9M | Buy |
45,600
+21,100
| +86% | +$8.82M | 0.03% | 621 |
|
|
2025
Q2 | $10.9M | Buy |
24,500
+14,200
| +138% | +$6.54M | 0.02% | 774 |
|
|
2025
Q1 | $4.99M | Sell |
10,300
-32,800
| -76% | -$15.3M | 0.01% | 1085 |
|
|
2024
Q4 | $17.4M | Buy |
43,100
+5,400
| +14% | +$2.5M | 0.04% | 524 |
|
|
2024
Q3 | $17.5M | Buy |
37,700
+34,100
| +947% | +$16.4M | 0.04% | 514 |
|
|
2024
Q2 | $1.69M | Sell |
3,600
-8,900
| -71% | -$3.86M | ﹤0.01% | 1706 |
|
|
2024
Q1 | $5.23M | Sell |
12,500
-10,300
| -45% | -$4.35M | 0.01% | 1091 |
|
|
2023
Q4 | $9.28M | Buy |
22,800
+4,700
| +26% | +$1.74M | 0.02% | 822 |
|
|
2023
Q3 | $6.29M | Buy |
18,100
+4,900
| +37% | +$1.71M | 0.02% | 960 |
|
|
2023
Q2 | $4.65M | Sell |
13,200
-7,800
| -37% | -$2.63M | 0.01% | 1006 |
|
|
2023
Q1 | $6.62M | Buy |
21,000
+600
| +3% | +$180K | 0.01% | 853 |
|
|
2022
Q4 | $5.89M | Sell |
20,400
-4,800
| -19% | -$1.46M | 0.02% | 966 |
|
|
2022
Q3 | $7.3M | Buy |
25,200
+4,400
| +21% | +$1.27M | 0.02% | 782 |
|
|
2022
Q2 | $5.86M | Sell |
20,800
-73,700
| -78% | -$19.7M | 0.02% | 923 |
|
|
2022
Q1 | $24.7M | Buy |
94,500
+85,500
| +950% | +$20.3M | 0.08% | 276 |
|
|
2021
Q4 | $1.98M | Sell |
9,000
-5,000
| -36% | -$972K | 0.01% | 1657 |
|
|
2021
Q3 | $2.54M | Sell |
14,000
-20,900
| -60% | -$4.08M | 0.01% | 1412 |
|
|
2021
Q2 | $7.04M | Sell |
34,900
-3,800
| -10% | -$795K | 0.03% | 620 |
|
|
2021
Q1 | $8.32M | Buy |
38,700
+31,200
| +416% | +$6.85M | 0.04% | 407 |
|
|
2020
Q4 | $1.77M | Sell |
7,500
-15,100
| -67% | -$3.46M | 0.01% | 1475 |
|
|
2020
Q3 | $6.15M | Buy |
22,600
+4,300
| +23% | +$1.19M | 0.03% | 475 |
|
|
2020
Q2 | $5.31M | Sell |
18,300
-800
| -4% | -$217K | 0.03% | 506 |
|
|
2020
Q1 | $4.54M | Sell |
19,100
-14,900
| -44% | -$3.42M | 0.04% | 419 |
|
|
2019
Q4 | $7.44M | Sell |
34,000
-16,400
| -33% | -$3.32M | 0.05% | 386 |
|
|
2019
Q3 | $8.54M | Buy |
50,400
+7,900
| +19% | +$1.4M | 0.07% | 249 |
|
|
2019
Q2 | $7.79M | Buy |
42,500
+19,200
| +82% | +$3.36M | 0.07% | 270 |
|
|
2019
Q1 | $4.29M | Buy |
23,300
+7,700
| +49% | +$1.42M | 0.03% | 581 |
|
|
2018
Q4 | $2.58M | Buy |
15,600
+14,000
| +875% | +$2.43M | 0.02% | 876 |
|
|
2018
Q3 | $308K | Buy |
1,600
+900
| +129% | +$160K | ﹤0.01% | 3386 |
|
|
2018
Q2 | $119K | Buy |
+700
| New | +$109K | ﹤0.01% | 3964 |
|
|
2016
Q4 | – | Sell |
-900
| Closed | -$79K | – | 5227 |
|
|
2016
Q3 | $79K | Buy |
900
+300
| +50% | +$28.4K | ﹤0.01% | 3465 |
|
|
2016
Q2 | $52K | Buy |
600
+100
| +20% | +$8.64K | ﹤0.01% | 3952 |
|
|
2016
Q1 | $40K | Hold |
500
| – | – | ﹤0.01% | 4028 |
|
|
2015
Q4 | $65K | Buy |
500
+300
| +150% | +$36.2K | ﹤0.01% | 3653 |
|
|
2015
Q3 | $20K | Buy |
+200
| New | +$25.7K | ﹤0.01% | 4083 |
|
|
2015
Q2 | – | Sell |
-900
| Closed | -$106K | – | 5181 |
|
|
2015
Q1 | $106K | Buy |
900
+800
| +800% | +$95.9K | ﹤0.01% | 2628 |
|
|
2014
Q4 | $12K | Sell |
100
-900
| -90% | -$101K | ﹤0.01% | 3864 |
|
|
2014
Q3 | $112K | Buy |
+1,000
| New | +$95.2K | ﹤0.01% | 2562 |
|
|
2014
Q2 | – | Sell |
-600
| Closed | -$42 | – | 4065 |
|
|
2014
Q1 | $42 | Sell |
600
-12,400
| -95% | -$982K | ﹤0.01% | 2802 |
|
|
2013
Q4 | $965K | Sell |
13,000
-3,200
| -20% | -$223K | 0.01% | 1120 |
|
|
2013
Q3 | $1.23M | Sell |
16,200
-2,200
| -12% | -$175K | 0.01% | 755 |
|
|
2013
Q2 | $1.47M | Buy |
+18,400
| New | +$1.36M | 0.01% | 714 |
|
Other funds holding VRTX
VCM
VPM
Walleye Trading's VRTX Position: Q1 2026 in Review
Walleye Trading sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 13,339 shares — an estimated $6.22M sold.
Walleye Trading first reported a position in VRTX in Q2 2013 and held it in 38 quarters. The position peaked at $19.8M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Walleye Trading reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Walleye Trading sold 13,339 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.22M.
- Walleye Trading first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 38 quarters.
- Walleye Trading's Vertex Pharmaceuticals position peaked at $19.8M in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.